Increased expression of serum gelsolin in patients with osteosarcoma

Chinese Medical Journal

Volumn 125, Issue 2, 2012, Pages 262-269

  Jin, Song ^a   Shen, Jing Nan ^b   Peng, Jian Qiang ^a   Wang, Jin ^b   Huang, Gang ^b   Li, Ming Tao ^c  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biological markers; Gelsolin; Osteosarcoma; Proteomics

Indexed keywords

GELSOLIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHILD; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OSTEOSARCOMA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; BLOTTING, WESTERN; CHILD; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GELSOLIN; HUMANS; MALE; OSTEOSARCOMA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862973391     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.02.019     Document Type: Article

References (38)

1. Unni KK, Dahlin DC. Grading of bone tumors. Semin Diagn Pathol 1984; 1: 165-172.
2. Winkler K, Beron G, Kotz R, Salzer-kuntschik M, Beck J, Beck W, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-624.
3. Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer WH. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 1992; 70: 2722-2727.
4. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568.
5. Guo D, Han J, Adam BL, Colburn NH, Wang MH, Dong Z, et al. Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress. Biochem Biophys Res Commun 2005; 337: 1308-1318.
6. Jiang XS, Tang LY, Dai J, Zhou H, Li SJ, Xia QC, et al. Quantitative analysis of severe acute respiratory syndrome (SARS)-associated coronavirus-infected cells using proteomic approaches: implications for cellular responses to virus infection, Mol Cell Proteomics 2005; 22: 112-200.
7. Tonge R, Shaw J, Middleton B, Rowlison R, Rayner S, Young J, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001; 1: 377-396.
8. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003; 3: 36-44.
9. Sharma K, Lee S, Han S, Lee S, Francos B, McCue P, et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy, Proteomics 2005; 5: 2648-2655.
10. Griffin TJ, Gygi SP, Ideker T, Rist B, Eng J, Hood L, et al. Complementary profiling of gene expression at the transcriptome and proteome levels in saccharomyces cerevisiae. Mol Cell Proteomics 2002; 1: 323-333.
11. Yu KH, Rustgi AK, Blair IA. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005; 4: 1742-1751.
12. Qian WJ, Jacobs JM, Camp DG 2nd, Monroe ME, Moore RJ, Gritsenko MA, et al. Comparative proteome analyses of human plasma following in vivo lipopolysaccharide administration using multidimensional separations coupled with tandem mass spectrometry. Proteomics 2005; 5: 572-584.
13. Yin HL, Stossel TP. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. Nature 1979; 281: 583-586.
14. Kwiatkowski DJ, Janmey PA, Yin HL. Identification of critical functional and regulatory domains in gelsolin. J Cell Biol 1989; 108: 1717-1726.
15. Yin H. Tubulin and associated proteins. In: Kreis T, Vale R Eds.Guidebook to the cytoskeletal and motor proteins. New York: Oxford University Press; 1999: 99-102.
16. Cunningham CC, Stossel TP, Kwiatkowski DJ. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 1991; 251: 1233-1236.
17. Kamada S, Kusano H, Fujita H, Ohtsu M, Koya RC, Kuzumaki N, et al. A cloning method for caspase substrates that uses the yeast two-hybrid system: cloning of the antiapoptotic gene gelsolin. Proc Natl Acad Sci USA 1998; 95: 8532-8537.
18. McGrath JL, Osborn EA, Tardy YS, Dewey CF Jr, Hartwig JH. Regulation of the actin cycle in vivo by actin filament severing. Proc Natl Acad Sci U S A 2000; 97: 6532-6537.
19. Dahl B, Schiodt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock 1999; 12: 102-104.
20. Lueck A, Brown D, Kwiatkowski DJ. The actin-binding proteins adseverin and gelsolin are both highly expressed but differentially localized in kidney and intestine. J Cell Sci 1998; 111: 3633-3643.
21. Mullauer L, Fujita H, Ishizaki A, Kuzumaki N. Tumor-suppressive function of mutated gelsolin in ras-transformed cells. Oncogene 1993; 8: 2531-2536.
22. Porter RM, Holme TC, Newman EL, Hopwood D, Wilkinson JM, Cuschieri A. Monoclonal antibodies to cytoskeletal proteins: an immunohistochemical investigation of human colon cancer. J Pathol 1993; 170: 435-440.
23. Shieh DB, Chen IW, Wei TY, Shao CY, Chang HJ, Chung CH, et al. Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 2006; 42: 599-606.
24. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly LJ, et al. Widespread loss of gelsolin in breast cancers of humans, mice and rats. Cancer Res 1996; 56: 4841-4845.
25. Mintzer E, Sargsyan H, Bittman R. Lysophosphatidic acid and lipopolysaccharide bind to the PIP2-binding domain of gelsolin. Biochim Biophys Acta 2006; 1758: 85-89.
26. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999; 40: 14-19.
27. Sagawa N, Fujita H, Banno Y, Nozawa Y, Katoh H, Kuzumaki N. Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10. Br J Cancer 2003; 88: 606-612.
28. Kamitani H, Taniura S, Watanabe K, Sakamoto M, Watanabe T, Eling T. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. Neuro Oncol 2002; 4: 95-101.
29. Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB. Downregulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treat 1999; 55: 179-188.
30. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, et al. Frequent loss of gelsolin expression in nonsmall cell lung cancers of heavy smokers. Cancer Res 1998; 58: 322-327.
31. Porter RM, Holme TC, Newman EL, Hopwood D, Wilkinson JM, Cuschieri A. Monoclonal antibodies to cytoskeletal proteins: an immunohistochemical investigation of human colon cancer. J Pathol 1993; 170: 435-440.
32. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995; 55: 3228-3232.
33. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999; 40: 14-19.
34. Chaponnier C, Gabbiani G. Gelsolin modulation in epithelial and stromal cells of mammary carcinoma. Am J Pathol 1989; 134: 597-603.
35. Zhang L, Zhou W, Velculescu VE, Kem SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997; 276: 1268-1272.
36. Kuzumaki N. Progress of research on tumor suppressor genes. Hokkaido Igaku Zasshi 1996; 71: 133-137.
37. Thor AD, Edgerton SM, Liu S, Moore DH, Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2010; 7: 2415-2424.
38. Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 2003; 3: 601-609.